New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
11:24 EDTABTAbbott presents promising Phase 2b Interferon-free hepatitis C results
Results from Abbott's phase 2b clinical trial, "Aviator," demonstrated high sustained viral response rates at 12 weeks post-treatment, SVR12, in all 8- and 12-week arms, with combinations of direct acting antivirals, DAAs, given with and without ribavirin, RBV. Results will be presented at the President's Press Conference and the latebreaking clinical trials session at the Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease, AASLD, in Boston.
News For ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
11:19 EDTABTAbbott board increases quarterly dividend to 24c from 22c
The board of Abbott increased the company's quarterly common dividend to 24c per share from 22c per share. The cash dividend is payable Feb. 13, 2015, to shareholders of record at the close of business on Jan. 15, 2015.
December 11, 2014
05:24 EDTABTAbbott IRIDICA now available in Europe
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use